Company
Headquarters: Taipei, Taiwan
CEO: Dr. James Chang Ph.D.
TW$16.53 Billion
TWD as of Jan. 1, 2026
US$527.6 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody that is in Phase II clinical trials for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase II clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which is in Phase I clinical trials for treating HIV infections; TMB-370, a bispecific neutralizing antibody that is in Phase I clinical trials to treat HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was founded in 2007 and is headquartered in Taipei, Taiwan.
TaiMed Biologics, Inc. has the following listings and related stock indices.
Stock: TWSE: 4147 wb_incandescent